Targeting the Root of Autoimmunity in Generalized Myasthenia Gravis: Pharmacist Strategies for Integrating FcRn Therapies Into Specialty Practice

Program Description

Generalized myasthenia gravis (gMG) is a chronic autoimmune neuromuscular disorder characterized by muscle weakness with diverse presentations across age groups and a significant impact on patients’ quality of life. Traditional treatment is guided by antibody confirmation and tailored to disease severity using acetylcholinesterase inhibitors, corticosteroids, immunosuppressants, or intravenous immunoglobulin (IVIg)/plasma exchange, while considering patient-specific factors. While current therapies for MG have significantly reduced mortality, many patients continue to face challenges such as incomplete remission, treatment-limiting adverse effects from steroids and immunosuppressants, and logistical barriers with IVIg or plasmapheresis that require reliable venous access. Newly approved biologics, including FcRn inhibitors, offer a novel route of administration with the potential for sustained efficacy, improved tolerability, and greater patient satisfaction compared with conventional regimens. It is essential for specialty pharmacists to be educated on new therapies for gMG because they play a central role in identifying appropriate patients, navigating access barriers, and ensuring safe, effective, and individualized treatment. This webinar will focus on the roles and responsibilities of specialty pharmacists in medication management and multidisciplinary collaboration in gMG. Strategies for integrating these emerging FcRn therapies into clinical practice and providing effective education to improve adherence to, access to, and affordability of new targeted therapies will be discussed.

Target audience: Specialty Pharmacist

Type of activity: Application
Release date: October 31, 2025
Expiration date: October 31, 2026

Time to complete activity: 1.0 hours

Learner level: Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

1. Determine the role of FcRn in the pathogenesis of generalized myasthenia gravis (gMG) and the mechanism of action of FcRn inhibitors
2. Analyze clinical trial data supporting the use of FcRn therapies for patients with anti-AChR antibody-positive gMG
3. Identify appropriate candidates for FcRn therapy based on clinical and biomarker criteria
4. Apply pharmacist-driven strategies to overcome access barriers and facilitate timely initiation of FcRn-targeted treatment